共 50 条
- [41] Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell CarcinomaCANCERS, 2021, 13 (22)Burcher, Kimberly M.Lantz, Jeffrey W.Gavrila, ElenaAbreu, ArianneBurcher, Jack T.Faucheux, Andrew T.Xie, AmyJackson, ClaytonSong, Alexander H.Hughes, Ryan T.Lycan, Thomas, Jr.Bunch, Paul M.Furdui, Cristina M.Topaloglu, UmitD'Agostino, Ralph T. B., Jr.Zhang, WeiPorosnicu, Mercedes
- [42] A very high tumor mutational burden (TMB) is associated with improved efficacy of PD-(L)1 inhibition across different PD-L1 expression subgroups and a distinct immunophenotype in NSCLC.CANCER RESEARCH, 2021, 81 (13)Ricciuti, BiagioArbour, Kathryn C.Mahadevan, Navin R.Alessi, Joao V.Lindsay, JamesUmeton, RenatoSinha, RileenHoojghan, AmirVokes, NatalieRecondo, GonzaloLamberti, GiuseppePolio, AndrewRizvi, HiraLeonardi, GiuliaPlodkowski, Andrew J.Felt, KristenSharma, BijayaTolstorukov, Michael Y.Janne, Pasi A.Van Allen, Eliezer M.Sholl, Lynette M.Rodig, Scott J.Hellmann, Matthew D.Awad, Mark M.
- [43] Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)Labriola, MatthewZhu, JasonGupta, RajanMcCall, ShannonJackson, JenniferWhite, James R.Weingartner, ElizabethKong, EricSimone, PeterPapp, EnikoGerding, KellySimmons, JohnGeorge, Daniel J.Zhang, Tian
- [44] Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Labriola, MatthewZhu, JasonGupta, RajanMcCall, ShannonJackson, JenniferWhite, James R.Weingartner, ElizabethKong, EricSimone, PeterPapp, EnikoGerding, KellySimmons, JohnGeorge, Daniel J.Zhang, Tian
- [45] Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinomaINTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 87Wang, YejinpengChen, LiangJu, LingaoXiao, YuWang, Xinghuan
- [46] PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersANNALS OF ONCOLOGY, 2018, 29 (10) : 2085 - 2091Sabari, J. K.Leonardi, G. C.Shu, C. A.Umeton, R.Montecalvo, J.Ni, A.Chen, R.Dienstag, J.Mrad, C.Bergagnini, I.Lai, W. V.Offin, M.Arbour, K. C.Plodkowski, A. J.Halpenny, D. F.Paik, P. K.Li, B. T.Riely, G. J.Kris, M. G.Rudin, C. M.Sholl, L. M.Nishino, M.Hellmann, M. D.Rekhtman, N.Awad, M. M.Drilon, A.
- [47] Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expressionCLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (01)Li, YunfengHu, MaitaoLi, LeiLiu, ShengHe, TingtingCheng, ChunyanXu, MianYin, Xinmin
- [48] Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysisMEDICINE, 2023, 102 (40) : E34990Li, WenjieZhao, YanjunZhang, HongjunZheng, WenyingWang, RuixuanGu, Xing
- [49] Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignanciesTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16Jeong, Ah-ReumTrando, Aaron H.Thomas, Sean D.Riviere, PaulSakowski, Patrick J.Sokol, Ethan S.Goodman, Aaron M.Kurzrock, Razelle
- [50] Incidence of high tumor mutation burden (TMB) and PD-L1 positivity in breast cancers and potential response to immune checkpoint inhibitors (ICPIs)CANCER RESEARCH, 2019, 79 (13)Sokol, EthanAlbacker, LeeSoyano, AixaParrondo, RicardoErnst, BrendaGabriel, EmmanuelFrampton, GarrettRoss, JeffreyAli, SirajChung, JonChumsri, Saranya